Approximately 75% of breast cancers express estrogen receptor α (ERα) and depend on estrogen signals for continued growth. Aromatase inhibitors (AIs) prevent estrogen production and inhibit ER signaling, resulting in decreased cancer recurrence and mortality. Advanced tumors treated with AIs almost always develop resistance to these drugs via the upregulation of alternative growth signals. The mechanisms that drive this resistance-especially epigenetic events that alter gene expression-are, however, not well understood. Genome-wide DNA methylation and expression analysis of cell line models of acquired AI resistance indicated that prostaglandin E 2 receptor 4 (PTGER4) is upregulated after demethylation in resistant cells. Knockdown and inhibitor studies demonstrate that PTGER4 is essential for estrogen-independent growth. Our exploratory analysis of downstream signaling indicates that PTGER4 likely promotes AI resistance via ligand-independent activation of the ERα-cofactor CARM1. We believe that we have discovered a novel epigenetic mechanism for altering cell signaling and acquiring endocrine therapy resistance. Our findings indicate that PTGER4 is a potential drug target in AI-resistant cancers. In addition, the epigenetic component of PTGER4 regulation suggests that further study of PTGER4 may yield valuable insights into how DNA methylation-targeted diagnoses and treatments can improve AI-resistant breast cancer treatment.
INTRODUCTION
Estrogen receptor α (ERα) is necessary for normal human breast development because of its role in processing estrogen growth signals. About 75% of breast tumors express and depend upon ERα. [1] [2] [3] Endocrine therapies that disrupt estrogen-ERα binding have a long record of clinical efficacy. Endocrine therapies can be divided into two broad classes: (1) selective ER modulators that competitively inhibit estrogen binding to ERα, and (2) aromatase inhibitors (AIs) that prevent the synthesis of estrogen. 3 AIs decrease recurrence and mortality in postmenopausal women when compared with selective ER modulators, such as tamoxifen. 4 Despite this increased efficacy, resistance to AI therapy occurs in nearly all of the advanced or metastatic tumors often through the activation of ligand-independent ER signaling. 5 Genetic analyses of both patient tumors and cell line models have revealed several mechanisms of acquired AI resistance. 5 Genomic alterations such as amplifications, mutations or translocations can activate ESR1 in low estrogen conditions. 6, 7 Ligandindependent ERα activation can also occur through activation of the phosphatidylinositol 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways at the cell membrane. 8 Activating mutations in the PI3K and MAPK pathways are frequently found in ERα-positive breast cancers. 9 MAPK signaling required for estrogen-independent growth can also be activated by upstream factors such as silencing of the cyclin-dependent kinase CDK10. 10 The downstream effectors of these pathways are responsible for phosphorylation of ERα, which activates it in the absence of estrogen. 11, 12 Despite improved understanding of potential genetic mechanisms leading to acquired AI resistance, potential epigenetic mechanisms of resistance are not well explored. Almost all cancers exhibit altered DNA methylation, an epigenetic mark that contributes to cancer development 13 and progression. 14 Epigenetic studies of endocrine therapy resistance have mostly focused on the direct silencing of ESR1 mediated by either DNA methylation or histone deacetylation. [15] [16] [17] [18] [19] [20] [21] [22] However, less is known about how epigenetic changes may contribute to the regulation of transcriptional networks in the development of acquired AI resistance.
In this work, we hypothesized that changes in DNA methylation contribute to acquired endocrine therapy resistance. Resistance to estrogen withdrawal was modeled in ERα-positive cancer cell lines that have been subjected to long-term estrogen deprivation (LTED). 23 LTED cell line models have facilitated the identification of mechanisms of acquired endocrine therapy resistance including increased ERα expression, 7 as well as increased signaling through PI3K, AKT and MAPK. [23] [24] [25] They also have been used to show that PI3K pathway inhibitors induce cell death in ERα-positive cell lines with oncogenic PI3K mutations, suggesting that targeting the PI3K pathway may improve treatment options for a subset of women. 23, 24 Genome-wide methylation and expression analysis of LTED cells identified hypomethylation correlated with increased expression of the prostaglandin E 2 receptor 4 gene (PTGER4) in LTED cells. EP4, the PTGER4 gene product, is a G-protein coupled receptor that activates adenylyl cyclase (AC) and protein kinase A (PKA) in response to prostaglandin E 2. 26 We find that EP4 activity is necessary for the proliferation of LTED cells. We also show that EP4 upregulation likely exerts its proliferative effect through PKAmediated activation of CARM1, which in turn binds to ERα and promotes ligand-independent activation of ER response genes. The significance of these molecular studies elucidating how EP4 is required for estrogen-independent growth was further demonstrated in the identification of PTGER4 upregulation in AI-resistant breast tumor samples. The loss of methylation and activation of PTGER4 represents a possible mechanism of acquired endocrine therapy resistance that can be therapeutically targeted.
RESULTS
DNA methylation is altered in a model of acquired resistance to endocrine therapy To understand potential epigenetic causes of acquired resistance to endocrine therapy, we performed genome-wide methylation and transcriptome analysis in MCF7 cells conditioned to grow in the absence of estrogen (MCF7-LTED, long-term estrogendeprived) (GSE45337, GSE74943). As MCF7 cells do not express aromatase (as verified by our RNA-seq data), AI resistance is modeled by estrogen withdrawal. After the removal of estrogen, most cells die; however, a few survive and eventually proliferate in the absence of estrogen. 23 Genome-wide methylation analysis using Methyl-MAPS 27 indicated genome-wide hypomethylation in MCF7-LTED compared with MCF7 cells with 245 644 CpG sites losing methylation and 28 751 sites gaining methylation. Analysis of these sites indicated that the majority of these changes occurred in transposable elements ( Supplementary Figure 1a ). Previously, it was shown that hypomethylation induced by 5-azacytidine increased estrogenindependent growth, 28 which suggests a general mechanism whereby methylation loss in breast tumors could contribute to estrogen-independent growth and thus endocrine therapy resistance. LTED cells upregulate ERα response genes and potential resistance genes RNA-seq analysis indicated 443 up-and 353 downregulated genes in MCF7-LTED cells relative to MCF7. We searched the promoters of up-and downregulated genes for methylation changes from 500 bp upstream to 1 kb downstream of the transcription start sites, as these regions often correlate with gene expression changes. 29, 30 Using stringent criteria, we identified seven genes with promoter methylation changes that associated with expression changes. Identified genes included PTGER4 and WISP2 (Supplementary Table 1 ). We validated correlations in PTGER4 by examining whether differentially methylated regions correlated with expression across 632 breast tumors and 98 normal breast tissue samples from The Cancer Genome Atlas (TCGA, Supplementary Figure S4 ). WISP2 showed a marked increase in methylation 3′ of the transcription start sites, which was accompanied by a marked decrease in expression (Supplementary Figure S3 ). It was previously shown that knockdown of WISP2, a WNT-signaling interacting protein, promoted estrogen-independent growth in MCF7 cells. 31 WNT signaling has been implicated in epithelial-mesenchymal transition, and ontology pathway analysis indicated that genes upregulated in MCF7-LTED cells were enriched for transforming growth factor-beta-dependent induction of epithelial-mesenchymal transition. However, visual inspection of MCF7-LTED cells did not indicate an obvious epithelial-mesenchymal transition phenotype and analysis of RNA-seq data showed they have a standard epithelial expression pattern: high expression of E-cadherin and no expression of vimentin, SNAIL, TWIST and Zeb1.
Instead, we focused on the PTGER4 gene that encodes the EP4 receptor. We chose EP4 because it showed the largest expression increase of the candidates, showed a strong and clear change in methylation and EP4 presents a potential druggable target. EP4 is a G-protein coupled receptor that activates AC and PKA in response to prostaglandin E 2 . 26 The PTGER4 gene has a CpG island associated with its promoter that lost methylation in the transition from MCF7 to MCF7-LTED ( Figure 1b ). Methylation changes were validated using Methyl-Screen (Supplementary Figure S2a ). 32 This loss of methylation is accompanied with a 420-fold gain in PTGER4 expression as indicated by RNA-seq (Figure 1a Figure S2b ). Furthermore, MCF7 cells treated with 5-azacytidine expressed higher levels of PTGER4 33 ( Supplementary Figure 8) , consistent with the hypothesis that DNA hypomethylation directly regulates expression. Increased mRNA levels in MCF7-LTED cells were accompanied with increases in EP4 protein expression as observed by immunofluorescence ( Figure 1b ). Increased EP4 expression in MCF7-LTED cells was also accompanied by increased cAMP in response to the EP4 agonist L-902 688 ( Figure 3b ).
EP4 inactivation decreases estrogen-independent cell growth in MCF7-LTED cells
We sought to determine whether EP4 knockdown would affect the ability of MCF7-LTED cells to grow without estrogen. EP4 was knocked down using two EP4-targeted small interfering RNAs (siRNAs) in both MCF7 and MCF7-LTED cells. Visual inspection indicated siEP4s drastically reduced cell proliferation in comparison with siRNA controls. We quantified the attenuated growth using reduction in alamarBlue to measure relative cellular proliferation 7 days after transfection (Figure 2a ). We verified knockdown at the mRNA level by RT-qPCR ( Figure 2b ). As appropriate antibodies could not be found for western blot analysis, we validated a decrease in EP4 protein by immunofluorescence ( Figure 2d ) and by measurement of the secondary messenger cAMP, which is produced as a result of EP4 activity (Figure 2c ). MCF7-LTED cells treated with siRNAs targeting EP4 mRNA showed a 61% and 59% average reduction in cell proliferation relative to control siRNAs (Po 10 -7 for each siRNA, Figure 2a ). These siRNAs showed no effect in MCF7 cells, which have negligible levels of EP4 expression at the mRNA and protein levels and thus provide a control for off-target effects.
We further validated the importance of EP4 for estrogenindependent growth in MCF7-LTED cells using two EP4-specific antagonists that do not inhibit other prostaglandin receptors: GW627368X and ONO-AE3-208. We observed an average 32% reduction in cellular proliferation for GW627368X-treated and an average 38% reduction for ONO-AE3-208-treated MCF7-LTED cells relative to vehicle alone (Po10 -7 for each antagonist, Figure 2e ). Again, MCF7 cells, which have negligible EP4 expression, showed no significant proliferation reduction when treated with antagonists.
Functional analysis of EP4 signaling in MCF7-LTED cells EP4 activates two pro-growth signaling pathways: PI3K and PKA; both of which could promote endocrine therapy resistance. MCF7-LTED cells show increased Akt and PI3K activity, and short-term estrogen-deprived MCF7 cells are sensitive to the BGT226 and BKM120 PI3K inhibitors. 23 In addition, EP4 activation can result in phosphorylation and activation of Akt. 26 However, our MCF7-LTED cells are resistant to the effects of the BGT226 and BKM120 PI3K inhibitors. 23 Analysis of Akt and PI3K phosphorylation also showed no changes after treatment of MCF7-LTED cells with EP4 antagonists (Figure 3a ). In addition, we did not find changes in mammalian target of rapamycin or MAPK signaling. This suggests that other pathways are likely activated by EP4 in our MCF7-LTED model.
We next hypothesized that PTGER4 may contribute to endocrine therapy resistance via AC. EP4 activates AC in addition to Akt, and AC activity can induce ERα phosphorylation. Once activated AC produces cAMP as its secondary messenger, and cAMP promotes proliferation through downstream effectors such as PKA. 26 We observed that both the concentration of cAMP in LTED cells and cell proliferation decreased after EP4 reduction by siRNA knockdown (Figures 2a and c ). This suggested that EP4 promotes proliferation in LTED cells via AC and cAMP. To confirm this, we applied the EP4-specific agonist L-902 688 to MCF7-LTED cells and observed a marked increase in cAMP, which was inhibited by EP4 with antagonists ( Figure 3b) .
A recent report showed that cAMP activates CARM1 via phosphorylation by PKA and drives ligand-independent ER transcriptional activity to promote resistance to tamoxifen. 34 CARM1 is an estrogen-dependent ER co-activator and phosphorylated CARM1 binds directly to the ERα hormone binding domain. 34 We thus tested whether a similar mechanism caused ligandindependent ER signaling in MCF7-LTED cells. CARM1 protein levels remained unchanged in MCF7-LTED and parental cells in the absence of estrogen even after treatment with EP4 antagonist (Figure 3c ). We found, however, that CARM1 acted as a PKA substrate in MCF7-LTED cells in the absence of estrogen and this interaction went away after treatment with EP4 antagonist. We further found that ERα showed a strong interaction between CARM1 and ERα in MCF7-LTED cells based on immunoprecipitation of CARM1 followed by immunoblotting with an ERα-specific antibody (Figure 3c ). Treatment with EP4 antagonist removed this interaction, suggesting that the CARM1-ERα interaction is dependent on EP4 signaling. As has been reported previously, 34 in estrogen-deprived conditions MCF7 cells showed no activation of CARM1 or association with ERα.
We next used chromatin immunoprecipitation (ChIP)-qPCR to interrogate the relationship between EP4 and ligand-independent binding of ERα in MCF7-LTED cells at two ERα-binding sites in the pS2 and PGR promoters. MCF7-LTED cells were treated with agonist or vehicle and subjected to ChIP-qPCR with antibodies to CARM1 or ERα at the pS2 promoter, the PGR promoter, and a negative control gene desert region on chr8q24 (Figures 3d and  e ). Both CARM1 and ERα were found to have increased binding upon treatment with EP4-specific agonist relative to cells treated with vehicle. No such gain was observed in the gene desert region. This implies that EP4 signaling can promote ligandindependent ER activity through CARM1. Further, knockdown of CARM1 reduced growth in MCF7-LTED cells (Figures 3f and g) .
ER signaling in MCF7-LTED cells
To understand whether ligand-independent ER signaling is active in MCF7-LTED cells, we used RNA-seq to compare gene expression in MCF7-LTED cells relative to MCF7 cells that recovered with the addition of estradiol after 1 day of estrogen deprivation. Using MCF7 cells treated with estradiol, we defined a signature of ER signaling based on genes upregulated twofold or more. Gene set enrichment analysis 35 shows that the majority of ER-responsive genes are also upregulated in MCF7-LTED (Po10 -7 , Supplementary Figure S6 ). This is consistent with the finding that MCF7-LTED cells are responsive to the ER antagonist fulvestrant 23 that ligand-independent ER signaling is active in MCF7-LTED cells at a genomic level.
and indicates
EP4 mRNA expression increased in ER+ breast cancer in the neoadjuvant setting To assess the potential clinical relevance of our findings, we tested the hypothesis that EP4 expression increases are associated with initial sensitivity to AI endocrine therapies. Expression profiling was performed for 104 patients before and after neoadjuvant AI therapy. Seventy-four tumors were 'aromatase inhibitor-resistant' and 30 were 'aromatase inhibitor-sensitive' based on the presence of the proliferation marker Ki67 after treatment (see details in Materials and methods section). Ki67 is a well-established indicator of clinical outcome in the neoadjuvant setting. 36 We observed that EP4 expression was higher in patients that demonstrated resistance to AI therapy versus patients that responded to AI therapy (Figure 4a ), which is consistent with EP4 expression having a role in AI resistance. Interestingly, EP4 expression also significantly increased during neoadjuvant therapy in both responder and non-responder tumor samples. This agrees with our observation that EP4 is upregulated immediately after estrogen deprivation in MCF7 cells (Supplementary Figure S7 ). Data from two smaller studies examining mRNA changes during neoadjuvant therapy verify this finding 37, 38 ( Figures 4b and c and Supplementary Figure S5 ). This suggests that in addition to promoting resistance to AIs, EP4 activation may be a response to the loss of ER signaling in ER+ tumors.
DISCUSSION
In this study, we examined the potential for DNA methylation to facilitate acquired endocrine therapy resistance via EP4 signaling. EP4 signaling also contributes to the proliferation of several cancer types including colon, lung, prostate, ovarian and breast. 26 Antagonists of EP4 have been shown to inhibit metastasis in hormone-resistant murine mammary tumor cells. 39 Further, the contribution of EP4 to endocrine therapy resistance via cell signaling is consistent with its role in the development of castration-resistant prostate cancer via PKA and cAMP. 40 Although our results focus on epigenetic regulation of the PTGER4 promoter as a means to activate ER, mutations are unlikely to have a major role in its activation. According to the COSMIC database, EP4 mutations are exceedingly rare in breast cancer, occurring in 0.33% of patients and copy number gains in 1.5%. 41 Sanger sequencing of PTGER4 in both MCF7 and MC7-LTED cells failed to uncover any mutations that could contribute to the increased activation of EP4. However, analysis of TCGA data indicates that PTGER4 methylation appears to accompany gene silencing in many breast tumors (Supplementary Figure S4) . Interestingly, PTGER4 is unmethylated and expressed in normal breast tissue. MCF7 cells treated with demethylating agents increase PTGER4 mRNA levels, consistent with DNA methylation having a direct role in its transcriptional regulation 33 (Supplementary Figure S8 ). This supports a mechanism whereby an upstream epigenetic change in the EP4 promoter regulates PTGER4 expression. Namely, an increase in DNA methylation that silences PTGER4 as the tumor forms followed by a decrease in methylation that reactivates the gene to promote resistance to estrogen withdrawal in LTED cells (Figure 1) .
Our exploratory analyses are consistent with a model whereby increased EP4 levels induce increased cAMP production, which in turn drives ligand-independent activation of ER through the PKA-mediated activation of the co-activator CARM1. Prior work has also indicated that PKA can activate ERα by direct phosphorylation of serines 236 (S236) and 305 (S305). When S236 is phosphorylated, ERα dimerization and DNA binding is still dependent on ligand 42 and thereby S236 phosphorylation is unlikely to activate ERα in MCF7-LTED cells. Studies in HeLa cells using a phosphomimetic S305E ERα suggested that S305 phosphorylation was sufficient to induce ligand-independent ERα binding to transcriptional targets in the absence of ERα dimerization. 43 However, other studies have instead suggested that S305 phosphorylated ERα is insufficient for ERα activation and that cofactors such as CARM1 34 in MCF7 cells and CREB 44 in CHO were required for ERα binding to DNA and activation of response elements. Further, there may be additional factors that collaborate to promote ER activity, such as the activation of cholesterol biosynthesis, which was recently shown to activate ligandindependent ER activity. 45 Although we cannot rule out the direct activation of ERα by PKA nor the activation of additional cofactors, our observations suggest that in estrogen-deprived conditions EP4 promotes ligand-independent activation of ERα through the PKA-mediated activation of the co-activator CARM1.
In addition to upregulation of EP4, another potential mechanism of ligand-independent ER activation is through genetic alterations of the ESR1 locus. Although any individual event is quite rare, as a whole these alterations are becoming an important theme in resistance. Metastatic tumors gain activating ESR1 ligand-binding domain mutations, especially after endocrine therapy. 6, [46] [47] [48] [49] Translocations of the ESR1 locus can fuse with coding sequence or constitutive promoters that activate ESR1 in the absence of estrogen. 6 ESR1 amplification has also been noted in both MCF7-LTED cells 7 and a xenograft line from a patient tumor resistant to AIs. 6 Further, remodeling of DNA methylation at ER-responsive binding elements is associated with endocrine therapy resistance. 50 Rather than contradict our findings, however, this indicates that MCF7-LTED cells remain dependent on ER signaling. Indeed, MCF7-LTED cells are sensitive to fulvestrant, an ER antagonist that accelerates proteasomal degradation of ER, and thereby show continued ER dependence. 23 In addition, gene set enrichment analysis of RNA-seq data from MCF7-LTED cells shows that MCF7-LTED cells have increased ER target gene expression. However, PTGER4 overexpression is not the only mechanism that supports ligand-independent ER activity.
Altogether, these data suggest that increased EP4 expression can promote the development of resistance to AI therapy. Expression increases in PTGER4 were associated with decreases in DNA methylation, which is consistent with the idea that DNA methylation has a regulatory role in PTGER4 expression. Furthermore, our data indicate that EP4 activation is necessary for estrogen-independent growth. Although we cannot completely rule out activation of alternative signaling pathways, our results support a mechanism by which EP4 acts through PKA and the co-activator CARM1 to drive ligand-independent ERα activation. EP4 signaling presents a potential therapeutic target for the treatment of AI-resistant breast cancer.
MATERIALS AND METHODS MCF7 and MCF7-LTED cells
MCF7 cells were from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 5% fetal bovine serum (Gibco, Thermo Fisher Scientific), 10 mM HEPES (Corning, Manassas, VA, USA), 4.5 g/l glucose (Corning), 2 mM L-glutamine (Gibco, Thermo Fisher Scientific), 1 mM sodium pyruvate (Corning) and 50 μg/ml gentamicin (Gibco, Thermo Fisher Scientific) in a humidified 37°C incubator containing 5% CO 2 . MCF7-LTED cells were derived from MCF7 cells through culture in LTED media for 49 months. 23 LTED media is the same as MCF7 media except with 5% charcoal stripped fetal bovine serum (Gibco, Thermo Fisher Scientific) and RPMI 1640 without phenol red (Gibco, Thermo Fisher Scientific). Cells tested negative for mycoplasma.
Methyl-MAPS genome-wide methylation analysis
Methyl-MAPS analysis was performed as in Edwards et al. with custombarcoded adaptors. 27 Libraries were made with AB-SOLiD and paired-end sequenced. Sequencing reads were demultiplexed and analyzed using custom perl scripts. 27 Sequencing statistics are in Supplementary Figure S1 .
RNA-seq
RNA-seq libraries were prepared using NEB Next RNA-seq kit (NEB, Ipswich, MA, USA) with custom barcodes and sequenced with an Illumina HiSeq. Reads were demultiplexed using custom perl scripts. Sequencing statistics are in Supplementary Figure S1 . Reads were mapped to the human genome (hg18) using TopHat (v1.4). 51 HT-seq was used to assign RefSeq annotations the reads. 52 Statistical analysis was performed using EdgeR. 53 Ontology analysis was performed with Metacore (Thomson Reuters, New York, NY, USA).
Immunofluorescence
Images were captured on a Zeiss AxioImager Z1 with AxioCam MRc (Zeiss, Oberkochen, Germany) and Axiovision software (Zeiss). The primary antibody was Cayman Chemical Company (Ann Arbor, MI, USA) 101775. The secondary antibody was Jackson ImmunoResearch (West Grove, PA, USA) 111-545-003.
Reverse transcriptase-quantitative PCR EP4 and CARM1 mRNA expression was assessed using Applied Biosystems Viia7 with SYBR green (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). Primer information is in Supplementary Table S2 . All qPCR measurements were performed in triplicate.
Cell proliferation
Silencer Select siRNAs were from Ambion (Ambion, Thermo Fisher Scientific, Waltham, MA, USA, siCtrl, 4390846; siEP4, 4427037: siEP4-1, ID s60396; siEP4-2, ID s11456; siCARM1, 4390824: siCARM1-1, s20577; siCARM1-2, s20579). siRNAs were transfected with Lipofectamine RNAiMax (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). When specified, EP4 antagonist GW627368X was used at 3.3 μM and ONO-AE3-208 was used at 10 μM. AlamarBlue assays were performed at 7 days for MCF7-LTED and 4 days for MCF7 cells. One-tenth volume of alamarBlue reagent (AbD Serotec BUF012, Bio-Rad, Oxford, UK) was added to each replicate. Eight replicates were performed for MCF7-LTED cells and four replicates for MCF7 cells. P-values were computed using a one-way analysis of variance followed post-hoc by Tukey's honest significant difference test. Bartlett's test of the homogeneity of variances was insignificant (alpha = 0.05) for all comparisons under the null hypothesis of equal variances.
Chromatin immunoprecipitation-qPCR
Cells were grown in 10 cm dishes to 85% confluence. The cells were starved by exchanging growth media for reduced serum media containing 0.5% charcoal stripped fetal bovine serum, for 18 h before activation of EP4 with 10 nM L-902 688 EP4 agonist (Cayman Chemical Company) for 2 h. An ethanol-treated sample served as a vehicle control. Afterward, cross-linking was initiated by drop-wise addition of 37% formaldehyde to a final concentration of 1% at room temperature. Cross-linking ran for 10 min and was quenched for 5 min at room temperature by adding 0.5 ml of 2.5 M glycine. Quenched cells were washed twice with 10 ml ice-cold phosphatebuffered saline, removed from the plate by scraping in ice-cold Dulbecco's phosphate-buffered saline (Gibco, Thermo Fisher Scientific) with protease inhibitors, and pelleted. Cell pellets were resuspended in 350 μl ChIP lysis buffer (1% sodium dodecyl sulfate, 10 mM EDTA, 50 mM Tris-HCl pH 8.0) with protease inhibitors. Lysed cells were sonicated and 100 μg of protein were brought to a final volume of 50 μl lysis buffer with protease inhibitors. In all, 9 μl of CARM1 antibody (Cell Signaling Technology, Danvers, MA, USA; (3H2) mouse mAb #12495) or 2 μl ER antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-7207X) was added and incubated overnight at 4°C. Antibody-bound proteins were purified by adding samples to 25 μl Protein A/G magnetic beads (Pierce, Thermo Fisher Scientific, Waltham, MA, USA) that were prewashed twice with ChIP dilution buffer. The samples were incubated with the beads 2 h at 4°C. Afterward the beads were washed with 0.5 ml of each of the following ice-cold buffers: (1) low salt immune complex wash buffer (EMD-Millipore, Billerica, MA, USA; 20-154), one wash; (2) high salt immune complex wash buffer (EMD-Millipore 20-155), one wash; (3) LiCl immune complex wash buffer (EMD-Millipore 20-156), one wash; (4) 1X TE-T, two washes (10 mM Tris-HCl, 1 mM EDTA, 0.1% Triton, pH 8). Elution buffer (1% sodium dodecyl sulfate+0.1 M NaHCO 3 ) was prepared fresh from 10X stocks. In all, 200 μl room temperature elution buffer was added, and the samples were incubated at room temperature for 30 min to elute the protein. Afterward, 1 μl of 10 mg/ml RNase A was added and the samples were incubated overnight at 65°C. The Qiagen PCR Purification kit (Qiagen, Hilden, Germany) was used to purify the DNA in a final volume of 60 μl Buffer EB.
RT-qPCR was performed on an Applied Biosystems Viia7 using SYBR green (Applied Biosystems, Thermo Fisher Scientific). Primers are in Supplementary Table S2 . Values are reported as percent relative to input. All experiments were performed in triplicate and P-values are computed using Student's t-test. cAMP measurements cAMP measurements were made using the Cyclic AMP XP Assay Kit (Cell Signaling Technologies). MCF7-LTED cells were washed twice with warm phosphate-buffered saline and then pre-treated with 0.5 mM IBMX in serum-free medium for 30 min before addition of L-902 688, at the indicated concentrations, or 1 μM forskolin. For combined antagonist/ agonist treatments, cells were pre-treated for 10 min with ONO-AE3-208 before addition of L-902 688. For EP4 knockdown experiments, cAMP measurements were made 2 days after transfection. cAMP measurements were quantitated as: %activity = 100 × [(A-A basal )/(A max -A basal )], where A is the absorbance of the agonist-treated sample, A max is the absorbance of the forskolin-treated sample and A basal is the absorbance of the vehicletreated sample.
CARM1-IP-ER blot
MCF7-LTED cells were grown to confluence in 10 cm dishes. Before harvesting, cells were grown in low serum media (0.5%). The next day, the cells were incubated with 10 ml of RPMI (no serum) containing 0.5 mM IBMX for 30 min. The cells were then treated with 10 nM L-902 688 in 10 ml of RPMI+0.5 mM IBMX and harvested after 0, 5, 15 or 30 min. After washing with ice-cold phosphate-buffered saline, cells were lysed with 1 ml of RIPA buffer (1 M Tris pH 8.0, 5 M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and 2 mM EDTA with freshly added phenylmethylsulfonyl fluoride to 1 mM final and 1X Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA, USA)). Cells were scraped loose, the cell lysate was transferred to a microcentrifuge tube and the tube was put on a rotator for 30 min at 4°C. The supernatant was isolated by centrifugation at 12 000 × g for 20 min at 4°C.
Immunoprecipitation was performed with a mouse anti-CARM1 (Cell Signaling Technologies #12495) and precipitated overnight at 4°C. Precipitated proteins were collected with Dynabeads Protein G magnetic beads. In all, 25 μl of beads were washed with 500 μl of RIPA buffer before adding the immunoprecipitated proteins. This was then incubated at 4°C for 3 h. The protein-bound beads were then washed three times with 0.5 ml RIPA with 10 mM NaF and 1 mM sodium pyrophosphate and resuspended in 0.5 ml of wash buffer. The protein was eluted in 40 ul of 2x NuPAGE LDS sample buffer at 90°C for 10 min. Final analysis of immunoprecipitated proteins occurred by western blot on 4-12% gradient PAGE gels (Life Tech., Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). ERα was identified using a rabbit polyclonal antibody (Santa Cruz Biotechnology sc-7207) to minimize signal from the mouse anti-CARM1 IgG used for immunoprecipitation. The blot was stripped using Restore Western Blot Stripping Buffer (Thermo Fisher Scientific), and reblotted with rabbit anti-CARM1 antibody (Cell Signaling Technologies #3379). Alexa Fluor 680 or Alexa Fluor 790-labeled secondary antibodies were from Jackson ImmunoResearch (West Grove, PA, USA). Blots were imaged using the Odyssey Fc (LI-COR Biosciences, Lincoln, NE, USA).
Expression analysis of ER+ breast cancer in neoadjuvant setting
Expression analysis was performed for patients enrolled in the POL 54 (NCT00084396) and ACOSOG (American College of Surgeons Oncology Group) Z1031 55 (NCT00265759) trials. Informed consent was obtained from all patients enrolled and ethics committee approval was obtained at all participating sites. Postmenopausal women with ER+ stage II/III breast cancer were treated with letrozole, anastrozole or exemestane for 16-18 weeks. Biopsies were performed before and after treatment. Patients were labeled as resistant if 10% or more of malignant cells stained positive for the proliferative marker Ki67 at 16 weeks. Expression analysis was performed using Agilent Human Gene Expression 4x44K v2 Microarray (Agilent Technologies, Santa Clara, CA, USA). P-values for PTGER4 expression levels were computed using two-sided Mann-Whitney U-test. Bartlett's test of the homogeneity of variances was insignificant (alpha = 0.05) for all comparisons under the null hypothesis of equal variances.
CONFLICT OF INTEREST
Dr Ellis has received consulting fees from Pfizer, Novartis and AstraZenica. He has ownership and patent income from Bioclassifier LLC for the PAM50 breast cancer test Prosigna sold by Nanostring. The remaining authors declare no conflict of interest.
